Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Preclinical and clinical studies demonstrate that co-administration of these peptides achieves superior reductions in bodyweight, appetite, and fasting glucose than either agent aloneachieving up to a 17% reduction in bodyweight in non-diabetic individuals and a 15.6% reduction in patients with type 2 diabetes over 2032 weeks
Beyond these three papers, review articles referencing the human peptides discovery in the 1970s continue to shape how researchers frame new hypotheses, particularly around why plasma concentration declines with age and what that means for tissue-repair capacity over time
The peptide's apparent stability across the gastric environment is part of why oral administration is sometimes argued for in this indication
Similarly compelling is the emergence of survodutide [13], a novel compound acting as a dual agonist for both glucagon receptors and glucagon-like peptide 1 receptors
Administration sites: Abdomen, thigh, or upper arm
